- Also known as
- Tirz · LY3298176 · GIP/GLP-1 dual agonist
- Class
- GIP and GLP-1 receptor agonist
- Form
- Lyophilised powder, as 20 mg and 40 mg vials
- Sizes
- 20 mg · 40 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 20 mg: 3 mL · 40 mg: 3 mL
What is Tirzepatide?
In the literature Tirzepatide is characterised as a GIP and GLP-1 receptor agonist. The work published on it is in human. Several names across the literature all denote the same material, among them Tirz, LY3298176 and GIP/GLP-1 dual agonist. Its sequence is recorded as Single long-acting peptide with activity at the GIP and GLP-1 receptors.. All 8 of the 8 studies set out below are controlled trials in people. We keep it as lyophilised powder in 20 mg and 40 mg vials; it is research material and nothing more. It is not a drug and is not provided for use in a person or an animal.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Jastreboff AM et al.2022 · N Engl J Med · PMID 35658024 | Human, phase 3 randomised controlled trial in adults with obesity, without diabetes (n=2539) — SURMOUNT-1 | 5, 10 or 15 mg once weekly, subcutaneous, vs placebo | 72 weeks, including a 20-week dose-escalation period | Mean weight change at week 72 was −15.0% (5 mg), −19.5% (10 mg) and −20.9% (15 mg) vs −3.1% with placebo. Adverse events, mostly gastrointestinal, led to discontinuation in 4.3% to 7.1% on tirzepatide vs 2.6% on placebo. |
| Jastreboff AM et al.2025 · N Engl J Med · PMID 39536238 | Human, phase 3 randomised controlled trial, obesity with prediabetes (n=1032 of 2539) — SURMOUNT-1, 3-year analysis | 5, 10 or 15 mg once weekly, vs placebo | 176 weeks, then 17 weeks off treatment | Weight change at 176 weeks was −12.3% to −19.7% vs −1.3% with placebo, and type 2 diabetes was diagnosed in 1.3% vs 13.3% (hazard ratio 0.07). No new safety signals were identified. |
| Rosenstock J et al.2021 · Lancet · PMID 34186022 | Human, phase 3 randomised controlled trial in type 2 diabetes on diet and exercise alone (n=478) — SURPASS-1 | 5, 10 or 15 mg once weekly, vs placebo | 40 weeks | HbA1c fell by 1.87%, 1.89% and 2.07% with 5, 10 and 15 mg vs a rise of 0.04% with placebo. An HbA1c below 7.0% was reached by 87–92% on tirzepatide vs 20% on placebo. |
| Frías JP et al.2021 · N Engl J Med · PMID 34170647 | Human, phase 3 open-label randomised trial vs semaglutide 1 mg in type 2 diabetes (n=1879) — SURPASS-2 | 5, 10 or 15 mg once weekly, vs semaglutide 1 mg once weekly | 40 weeks | HbA1c fell by 2.01 to 2.30 percentage points with tirzepatide vs 1.86 with semaglutide, and weight loss was 1.9 to 5.5 kg greater. Nausea was reported by 17–22% on tirzepatide and 18% on semaglutide. |
| Aronne LJ et al.2024 · JAMA · PMID 38078870 | Human, phase 3 randomised withdrawal trial in obesity, without diabetes (n=670 randomised) — SURMOUNT-4 | Maximum tolerated dose of 10 or 15 mg once weekly, subcutaneous, then continued or switched to placebo | 36-week open-label lead-in plus 52 weeks double-blind | After a mean 20.9% reduction in the lead-in, weight changed by −5.5% with continued tirzepatide vs +14.0% after switching to placebo from week 36 to 88. Withdrawal led to substantial regain of lost weight. |
| Malhotra A et al.2024 · N Engl J Med · PMID 38912654 | Human, two phase 3 randomised controlled trials in moderate-to-severe obstructive sleep apnoea with obesity — SURMOUNT-OSA | Maximum tolerated dose of 10 or 15 mg, vs placebo | 52 weeks | The apnoea-hypopnoea index fell by 25.3 and 29.3 events per hour with tirzepatide vs 5.3 and 5.5 with placebo in the two trials. Adverse events were mostly gastrointestinal and mild to moderate. |
| Packer M et al.2025 · N Engl J Med · PMID 39555826 | Human, randomised controlled trial in heart failure with preserved ejection fraction and obesity (n=731) — SUMMIT | Up to 15 mg once weekly, subcutaneous, vs placebo | At least 52 weeks (median follow-up 104 weeks) | Cardiovascular death or worsening heart failure occurred in 9.9% on tirzepatide vs 15.3% on placebo (hazard ratio 0.62). Adverse events leading to discontinuation were 6.3% vs 1.4%. |
| Loomba R et al.2024 · N Engl J Med · PMID 38856224 | Human, phase 2 randomised controlled trial in biopsy-confirmed MASH with F2–F3 fibrosis (n=190) — SYNERGY-NASH | 5, 10 or 15 mg once weekly, subcutaneous, vs placebo | 52 weeks | Resolution of MASH without worsening of fibrosis was seen in 44%, 56% and 62% on 5, 10 and 15 mg vs 10% on placebo. The authors state that larger and longer trials are needed. |
What these studies don't show: Controlled human data does exist, yet its scope is narrow. Selected groups and surrogate endpoints cap how far these results can be extended. None of it settles safety beyond the specific conditions of each trial. Purity data verifies what sits in the vial and says nothing about whether a compound has any effect.
Every study links to its PubMed record. See all Tirzepatide studies in the research library →
Tirzepatide price in Canada: 20mg and 40mg vials
Buy Tirzepatide in Canada in 2 vial sizes and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 20 mg | $77.50 | $3.88/mg |
| 40 mg | $87.00 | $2.17/mg |
Starter kit
Is Tirzepatide available in Canada?
Tirzepatide is authorized as a prescription medicine in Canada. Its Canadian authorization is as MOUNJARO (Eli Lilly Canada), DIN 02532921, in the KwikPen presentations. That authorization applies to the licensed product rather than research material, and Borealis Peptides provides this for laboratory work only. How Health Canada treats research peptides →
Side effects reported in studies
The studies cited below set out their own tolerability observations, and those statements appear here exactly as written. Human work on this scale does not pin down a safety profile.
Tirzepatide FAQ
What is Tirzepatide?
Both suppliers and the literature record Tirzepatide as a GIP and GLP-1 receptor agonist. Its published work is in human. Borealis Peptides provides it as lyophilised powder in 20 mg and 40 mg vials for in-vitro laboratory research. It holds no authorization as a medicine and is not for use in any living subject. The table on this page lays out each study with its model and the result it reported.
Where can I buy Tirzepatide in Canada?
Straight from Borealis Peptides, kept in Canadian stock so nothing crosses a border to reach you. Available in 20 mg and 40 mg vials. Purity is verified by HPLC one batch at a time, and we supply for laboratory research only.
Is Tirzepatide legal in Canada?
Tirzepatide is authorized as a prescription medicine in Canada. Its Canadian authorization is as MOUNJARO (Eli Lilly Canada), DIN 02532921, in the KwikPen presentations. That authorization applies to the licensed product rather than research material, and Borealis Peptides provides this for laboratory work only. Because Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, we read it as marking what the material is meant for, not clearance for use. Establishing lawful use in your own setting is down to you.
How much Tirzepatide should I use?
We will not answer dosing questions. Tirzepatide is not provided for use in a person or an animal, so there is no dose to describe. What this page carries is the amount each cited study used and the model it was used in, reproduced as the authors published it.
What human evidence is there for Tirzepatide?
Of the 8 studies cited, 8 are controlled trials in people, with the remainder being animal or cell work. Every row states its model, the amount used and the authors' reported finding, so each study's weight can be assessed first-hand instead of through a summary.
How long does Tirzepatide keep?
Keep sealed vials at −20 °C, dry and dark. Once in solution, store at 2–8 °C. As a dry powder it travels at room temperature and is chilled on arrival. Keeping it dark and at an even temperature counts for more than how quickly it reached you.
How is the purity of Tirzepatide confirmed?
Each batch is HPLC tested before sale, and the certificate refers to the batch in your vial rather than to the product as a whole. Filing that batch number with your records is what lets an observation be reproduced later. Certificates are available on request.
How does Tirzepatide compare with Retatrutide and Cagrilintide?
They are distinct compounds with distinct literatures, and no ranking is offered here. Retatrutide and Cagrilintide have 6 cited studies and 8 cited studies on their page against 8 here. The comparison that helps is between the two study tables and the models behind them.







